Urgency, cause, and the transplant pathway always come first
Stem cell therapy for liver failure in Istanbul, Turkey
Our Istanbul hepatology team protects your transplant pathway and complication control before discussing any early-stage cell therapy research.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Evidence position
What is known, what is investigational, and what is not demonstrated
Transplant-first, honest evaluation
Confusion, bleeding, fever, worsening jaundice, or kidney decline always mean urgent hospital care first, and we act on that immediately.
Portal and hepatic routes are invasive
Acute liver failure, decompensated cirrhosis, and ACLF are different clinical states, and we plan around your exact one.
IV doesn't mean liver engraftment
Results vary between patients and stem cell therapy is not a guaranteed cure — a lab change alone doesn't prove liver regeneration.
Clinical map
Start with the diagnosis, stage, and treatment context
Cause-specific hepatology care, complication control, and timely transplant referral are never delayed in our program.
Established care comes first
- Treat the cause: We coordinate specialist care for viral, alcohol-related, autoimmune, or metabolic liver disease.
- Control complications: We help manage ascites, varices, encephalopathy, infection, and kidney risk.
- Transplant evaluation: We use MELD-Na, clinical trajectory, and multidisciplinary assessment without avoidable delay.
- 01
Acute liver failure
Rapid coagulopathy and encephalopathy without prior cirrhosis needs specialist intensive care and urgent transplant-center input.
- 02
Decompensated cirrhosis
Ascites, variceal bleeding, and jaundice define high-risk disease that we monitor closely.
- 03
Acute-on-chronic liver failure
An acute insult with organ failure has high short-term risk and needs immediate hospital management.
Direct answer
What the current evidence says
We never let an experimental cell option delay cause-specific hepatology care, complication control, or timely transplant referral. Acute liver failure and acute-on-chronic liver failure can be emergencies, and we treat them that way. Human cell studies use varied products and endpoints, so we're candid that preliminary signals don't support a generic IV or exosome claim. Request your free medical evaluation for a transplant-first, honest review.
Evidence ledger
Read the actual study, including the result that did not change
Each row keeps product identity, route, endpoint, and limitation together so one trial cannot become a generic treatment claim.
01 Cochrane review of human stem cells for decompensated cirrhosis
Open source- Product
- Multiple bone marrow, cord, MSC, mononuclear, and selected-cell products
- Route
- Multiple study-specific routes and schedules
- Design
- Systematic review and meta-analysis of randomized clinical trials
- Finding
- The review found very low-certainty evidence and could not determine the effects on mortality, serious adverse events, quality of life, complications, or liver function with confidence.
- Limitation
- Products, routes, disease states, trials, and outcomes were heterogeneous, with insufficient data for reliable efficacy conclusions.
Product and route
A mechanism is not a clinical outcome
- 01
Portal and hepatic routes are invasive
Bleeding, thrombosis, and decompensation risks require hospital and hepatology oversight, which we provide as standard.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
- 02
IV doesn't mean liver engraftment
We won't imply an infusion homes to the liver or restores synthetic function without proof.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
Outcomes before travel
Decide what meaningful change would look like
A baseline and a time point matter more than an isolated testimonial. These measures should be chosen before any intervention.
- 01
MELD-Na and Child-Pugh components
- 02
Ascites, encephalopathy, bleeding, infection, and kidney events
- 03
Hospitalization and transplant listing
- 04
Frailty, nutrition, and quality of life
- 05
Transplant-free survival and treatment side effects
Specialist review
What a complete Istanbul review needs
Our Istanbul hepatology team protects your transplant pathway and complication control before discussing any early-stage cell therapy research.
Records and baseline
- Cause, duration, biopsy or imaging, and current liver diagnosis
- MELD-Na, bilirubin, INR, creatinine, sodium, albumin, and trend
- Ascites, varices, encephalopathy, infection, and liver cancer assessment
- Current medicines, alcohol status, nutrition, and transplant evaluation
- The exact product, route, and rescue plan we recommend for you
Safety and planning checks
- We advise against elective travel with acute liver failure, ACLF, active bleeding, or circulatory instability.
- Your Istanbul review involves hepatology and preserves your home transplant pathway.
- Any quote separates experimental product costs from hospital, intensive care, and long-term follow-up.
Transparent planning
Build the medical plan before the package
A quote should follow record review, product disclosure, route rationale, and a written follow-up plan. This page does not invent a universal price.
- We advise against elective travel with acute liver failure, ACLF, active bleeding, or circulatory instability.
- Your Istanbul review involves hepatology and preserves your home transplant pathway.
- Any quote separates experimental product costs from hospital, intensive care, and long-term follow-up.
Questions the plan must answer
- 01
Portal and hepatic routes are invasive: Bleeding, thrombosis, and decompensation risks require hospital and hepatology oversight, which we provide as standard.
- 02
IV doesn't mean liver engraftment: We won't imply an infusion homes to the liver or restores synthetic function without proof.
Primary reading
Guidelines, trials, and regulatory context
FAQ
Questions patients ask before an Istanbul review
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.